CytoSorbents

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin on April 25, 2002 and is headquartered in Princeton, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

CytoSorbents reports growth in treatments and sales despite margin challenges

CytoSorbents demonstrated strong performance in treatment deliveries and sales momentum, despite margin challenges.
The company's focus on R&D and regulatory expertise positions it well for future growth opportunities.
Operational improvements and market expansion efforts are key to overcoming current challenges and driving profitability.
With a favorable competitive position and strategic initiatives, CytoSorbents aims to capitalize on emerging market opportunities.

CytoSorbents reports robust Q1 performance and eyes market expansion

CytoSorbents demonstrated strong performance in Q1 2023 with notable revenue and treatment milestones, alongside strategic market expansion efforts.
While facing challenges such as declining gross margins and managing costs, the company is focused on leveraging opportunities for growth and profitability.
Overall, CytoSorbents' financial health, product advancements, and market strategies position it well for future success and market expansion.

CytoSorbents reports robust Q2 earnings, eyes U.S. market expansion

CytoSorbents' Q2 2023 performance reflects strong revenue growth, operational milestones, and strategic partnerships driving future expansion.
While facing challenges in managing cash burn and regulatory hurdles, the company is well-positioned to capitalize on market opportunities.
With a focus on product innovation, market expansion, and financial sustainability, CytoSorbents aims to drive continued growth and market success.

CytoSorbents excels in Q3, eyes FDA approval and market expansion

CytoSorbents reported strong financial performance in Q3 2023, with revenue growth and a robust gross margin.
The company's focus on critical care markets and progress in the STAR-T trial indicate promising growth potential.
Challenges lie in maintaining cash reserves, securing FDA approvals, and navigating market competition.
Opportunities include expanding product portfolio, exploring capital sources, and leveraging favorable market conditions in Canada.

CytoSorb reports revenue growth and margin improvement in 2023

CytoSorb showed solid performance in 2023 with revenue growth and margin improvement.
Strategic partnerships and government support position the company for future growth.
Challenges include distributor order delays and market uncertainties in Germany.
Opportunities lie in new product initiatives, regulatory submissions, and international expansion.

CytoSorbents reports robust Q1 performance, eyes FDA submissions for growth

CytoSorbents delivered strong financial and operational performance in Q1 2024, driven by revenue growth and improved margins.
While facing challenges such as lower grant income and the need to maintain consistent performance, the company is well-positioned to capitalize on growth opportunities.
With a focus on innovation, market expansion, and financial prudence, CytoSorbents aims to sustain its positive momentum throughout the year.

CytoSorbents reports revenue growth and operational improvements in Q2 2024

CytoSorbents' Q2 2024 showed positive revenue growth, operational improvements, and strategic advancements.
The company's focus on financial stability, regulatory progress, and cost efficiency bodes well for future performance.
While challenges like operational losses and regulatory hurdles persist, opportunities for growth and optimization are evident.
Overall, CytoSorbents is positioned for continued growth and success with a solid financial foundation and strategic direction.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CytoSorbents Corp. engages in critical care immunotherapy, investigation, and commercialization of blood purification technology. Its product portfolio includes CytoSorb, ContrastSorb XL, HemoDefend, VetResQ, and DrugSorb. The company was founded by Joseph Rubin in August 1997 and is headquartered in Princeton, NJ.

CytoSorbents (CTSO) delivered earnings and revenue surprises of -78.57% and 11.15%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CytoSorbents (CTSO) Reports Q2 Loss, Lags Revenue Estimates

Fresenius Medical Care

Fresenius Medical Care and CytoSorbents have expanded their partnership via a multi-stage collaboration designed to seize new sales opportunities and jointly develop future innovations CytoSorb will be featured on Fresenius Medical Care's critical care platforms for the removal of cytokines, bilirubin, and myoglobin Fresenius Medical Care will be responsible for the specific worldwide marketing and combined promotion of CytoSorb with its critical care products utilizing multiple highly visible and prominent marketing channels and campaigns CytoSorbents' proprietary hemoadsorption CytoSorb therapy expands the dimensions of blood purification of the Fresenius Medical Care critical care product portfolio BAD HOMBURG V.D. HÖHE, GERMANY and PRINCETON, N.J.

CytoSorb® Becomes a Featured Blood Purification Therapy on Fresenius Medical Care Critical Care Platforms

PRINCETON, N.J. , Aug. 2, 2022 /PRNewswire/ -- CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today reported unaudited financial and operating results for the quarter ended June 30, 2022.

CytoSorbents Reports Second Quarter 2022 Financial and Operational Results

PRINCETON, N.J. , July 25, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report second quarter 2022 operating and financial results after the market close on August 2 nd, 2022.

CytoSorbents to Report Second Quarter 2022 Operating and Financial Results

PRINCETON, N.J. and BERLIN , July 8, 2022 /PRNewswire/ -- During the recent 2022 CytoSorb Users' Meeting in Berlin, Germany hosted by CytoSorbents Corporation (NASDAQ: CTSO), leading critical care specialists, cardiac surgeons, and research scientists from around the world highlighted the use of CytoSorb® blood purification across a broad range of applications driven by major current trends in healthcare.

The 2022 CytoSorb World Users' Meeting Highlights the Broad Market Potential of CytoSorb as an Interdisciplinary Therapeutic Approach

The 2022 CytoSorb World Users' Meeting focuses on groundbreaking new applications of the adsorption technology to celebrate the 10th anniversary of commercialization PRINCETON, N.J. and BERLIN , July 1, 2022 /PRNewswire/ -- Under the theme "We Are Changing Medicine: CytoSorb Therapy - From the Past to the Future," CytoSorbents Corporation (NASDAQ: CTSO) is bringing together nearly 300 of the world's leading critical care physicians and renowned scientists, as well as some of the most experienced cardiovascular and liver specialists to the 2022 CytoSorb World Users' Meeting (WUM) on July 2, 2022 in Berlin, Germany.

Leading Critical Care and Cardiac Surgery Specialists from 40 Countries Meet to Discuss CytoSorb and the New Dimension in Blood Purification

Carrols Restaurant Group

WidePoint

The Nasdaq Composite dropped by more than 400 points on Friday. Investors, meanwhile, focused on some notable insider trades.

3 Stocks Under $3 Insiders Are Aggressively Buying

Standard BioTools Inc

ReWalk Robotics

Sunshine Biopharma

Troika Media Group

Insiders are buying these penny stocks. The post 10 Top Penny Stocks To Buy In June According To These Insiders Part 1 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

10 Top Penny Stocks To Buy In June According To These Insiders Part 1

PRINCETON, N.J. , June 2, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will host its Annual Meeting virtually on Tuesday, June 7, 2022, at 10:00 a.m.

CytoSorbents to Hold 2022 Annual Meeting of Stockholders Virtually

Stand-alone Blood Pump Business Model is expected to Enable Expanded Use and Increased Adoption of CytoSorb ® PRINCETON, N.J. , June 1, 2022 /PRNewswire/ -- CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today announced that following a successful pilot program in three countries, the Company has signed an expanded non-exclusive agreement with Nikkiso Europe GmbH (Nikkiso) to distribute their PureADJUST stand-alone hemoperfusion pump and accessories in a total of 14 countries.

CytoSorbents Partners with Nikkiso to Distribute the PureADJUST Hemoperfusion Blood Pump and Supplies in 14 Countries

MONMOUTH JUNCTION, N.J. , May 19, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces management will present at two upcoming in–person investor conferences.

CytoSorbents to Present at Two Upcoming Investor Conferences

Cytosorbents Corporation (NASDAQ:CTSO ) Q1 2022 Earnings Conference Call May 3, 2022 4:30 PM ET Company Participants Terri Anne Powers - Vice President, Investor Relations & Corporate Communications Phillip Chan - Chief Executive Officer Vincent Capponi - President & Chief Operating Officer Kathleen Bloch - Chief Financial Officer Christian Steiner - Executive Vice President, Sales & Marketing and Managing Director of Cytosorbents Europe Christopher Cramer - Vice President, Business Development Efthymios Deliargyris - Chief Medical Officer Conference Call Participants Frank Pinal - Jefferies Justin Walsh - B. Riley Securities Zach Weiner - Jefferies Priya Sachdeva - SVB Operator Good afternoon and welcome to the Cytosorbents Corp.'s First Quarter 2022 Earnings Conference Call.

Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q1 2022 Results - Earnings Call Transcript

Q1 2022 total revenue was $8.7 million, including product sales of $7.9 million.  Core non-COVID-19 product sales were an estimated $7.6 million, and on a constant currency basis were comparable to core product sales a year ago.

CytoSorbents Reports First Quarter 2022 Results and Revises 2022 Outlook

MONMOUTH JUNCTION, N.J. , May 2, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced that the Company has been awarded a new preferred supplier agreement for CytoSorb® with the Asklepios Group (Asklepios), one of the largest private hospital operators in Germany, following the majority acquisition of  RHÖN‑KLINIKUM AG in 2020.

CytoSorbents Awarded Preferred Supplier Agreement with Asklepios, One of the Largest Private Hospital Operators in Germany

MONMOUTH JUNCTION, N.J. , April 29, 2022 /PRNewswire/ -- CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in intensive care and cardiac surgery using blood purification via its proprietary polymer adsorption technology, announced today that the first patient has been enrolled in the Safe and Timely Antithrombotic Removal-Direct Oral Anticoagulants (STAR-D) double-blind, randomized, controlled clinical trial designed to support FDA marketing approval of the DrugSorb™-ATR Antithrombotic Removal System for intraoperative removal of apixaban and rivaroxaban during cardiothoracic surgery.

First Patient Enrolled in U.S. STAR-D Pivotal Trial Evaluating the DrugSorb™-ATR Antithrombotic Removal System to Remove Apixaban and Rivaroxaban During Cardiothoracic Surgery

MONMOUTH JUNCTION, N.J. , April 28, 2022 /PRNewswire/ -- CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced that the Company will participate in the 10th EuroELSO Congress (EuroELSO 2022) in London, UK being held May 4-6, 2022, one of the two major conferences for ECMO (extracorporeal membrane oxygenation) users worldwide.

CytoSorbents Highlights the Strategy of "Enhanced Lung Rest" Using CytoSorb with ECMO to Help Treat Lung Failure at the 10th EuroELSO Congress

MONMOUTH JUNCTION, N.J. , April 19, 2022 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2022 operating and financial results after the market close on May 3, 2022.

CytoSorbents to Report First Quarter 2022 Operating and Financial Results

MONMOUTH JUNCTION, N.J. , April 14, 2022 /PRNewswire/ -- CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces that it has registered a new subsidiary, CytoSorbents Medical UK Limited, with plans to establish a direct sales presence within the United Kingdom (UK) and Ireland.

CytoSorbents To Expand Direct Sales of CytoSorb® to the United Kingdom, the Sixth Largest Medical Device Market in the World

MONMOUTH JUNCTION, N.J. , April 7, 2022 /PRNewswire/ -- CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has received approximately $740,000, net of transactions costs, in cash proceeds from the sale of its 2020 Net Operating Loss (NOL) and R&D tax credits from the Technology Business Tax Certificate Transfer Program, sponsored by the New Jersey Economic Development Authority (NJEDA).

CytoSorbents Receives Approximately $740,000 from the New Jersey Business Tax Certificate Transfer Program

MONMOUTH JUNCTION, N.J. , April 5, 2022 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces the appointment of Ms.

CytoSorbents Appoints Jiny Kim, MBA to its Board of Directors

MONMOUTH JUNCTION, N.J. , March 17, 2022 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced that the Company will participate in the 41st International Symposium on Intensive Care and Emergency Medicine (ISICEM 2022) Congress in Brussels, Belgium being held March 22-25, 2022.

CytoSorbents Highlights Activities at the Live 41st International Symposium on Intensive Care and Emergency Medicine (ISICEM)

Cytosorbents Corporation (CTSO) CEO Phillip Chan on Q4 2021 Results - Earnings Call Transcript

MONMOUTH JUNCTION, N.J., March 8, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorption technology, today reported audited financial and operating results for the quarter and year ended December 31, 2021 and provides its 2022 outlook.

CytoSorbents Reports Fourth Quarter and Full Year 2021 Results and Provides 2022 Outlook

MONMOUTH JUNCTION, N.J., Feb. 8, 2022 /PRNewswire/ --  CytoSorbents Corporation  (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fourth quarter and full year 2021 operating and financial results after the market close on March 8, 2022.

CytoSorbents to Report Fourth Quarter and Full Year 2021 Operating and Financial Results

MONMOUTH JUNCTION, N.J., Feb. 3, 2022 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announces management will participate in two upcoming virtual investor conferences.

News for CytoSorbents Stock (CTSO)